• 1
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Database: incidence SEER 9 Registries public-use. Nov 2002 Sub (1973–2000)—National Cancer Institute, released April 2003, based on the November 2002 submission. Available at URL: [accessed March 2005].
  • 2
    Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975-2000. Bethesda: National Cancer Institute, 2003.
  • 3
    Brenner H, Hakulinen T. Advanced detection of time trends in long-term cancer patient survival: experience from 50 years of cancer registration in Finland. Am J Epidemiol. 2002; 156: 566577.
  • 4
    Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th Century: a period analysis. Lancet. 2002; 360: 11311135.
  • 5
    Brenner H, Soderman B, Hakulinen T. Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland. Int J Epidemiol. 2002; 31: 456462.
  • 6
    Brenner H, Hakulinen T. Very-long-term survival rates of patients with cancer. J Clin Oncol. 2002; 20: 44054409.
  • 7
    Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961; 6: 101121.
  • 8
    Klein JP, Moeschberger ML. Survival analysis techniques for censored and truncated data. New York: Springer-Verlag, 1997.
  • 9
    Cronin K, Mariotto A, Scoppa S, Green D, Clegg L. Differences between Brenner et al. and NCI Methods for calculating period survival. Technical report 2003-02. Bethesda: Statistical Research and Application Branch, National Cancer Institute, 2003.
  • 10
    Hakulinen T, Tenkanen L. Regression analysis of relative survival rates. Appl Stat. 1987; 36: 309317.
  • 11
    Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000; 11: 167170.
  • 12
    Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002; 20: 11921202.
  • 13
    American Joint Committee on Cancer. Manual for staging of cancer, 3rd ed. Philadelphia: Lippincott, 1988.